DaVita Inc. Increases Offering of $1 Billion Senior Notes with Pricing Details

DaVita Inc. Upsizes and Prices $1 Billion Senior Notes Offering

DENVER, May 20, 2025 – DaVita Inc. (NYSE: DVA) has recently disclosed significant updates regarding its private offering of senior notes. Originally set at $750 million, the company has upsized the offering to $1 billion. The company has priced the notes, which carry a 6.750% interest rate, at 100% of their face value. These senior notes, due in 2033, are set to close on May 23, 2025, pending the fulfillment of standard closing conditions.

Purpose of the Offering

The proceeds from this offering are designated for several strategic financial activities. DaVita intends to use the net proceeds primarily to repay existing borrowings under its revolving credit facility, settling any related accrued interest. Additionally, the funds will cover associated costs and may be allocated towards general corporate needs. This includes potential share buybacks, working capital maintenance, and capital expenditures.

Compliance and Regulations

Importantly, the seniors notes will be available solely to qualified institutional buyers under Rule 144A of the Securities Act of 1933 and to specific non-U.S. persons, in compliance with Regulation S. It is worth noting that the notes will not be registered under the Securities Act or any other national securities laws, which means they cannot be sold or offered in the United States without proper registration or exemptions.

The Company Profile

DaVita Inc. stands at the forefront of the healthcare sector, specializing in kidney care. With over 25 years of service, DaVita emphasizes enhancing patient care worldwide. Their facilities cater to all stages of kidney health, ranging from slowing disease progression and ensuring successful transplants to providing acute care in hospitals and offering at-home dialysis services. The commitment to clinical quality and continuous innovation underscores DaVita's role as a leader in the healthcare landscape.

Forward-Looking Statements

This announcement includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements encompass expectations about the offering, intended uses for the proceeds, and the anticipated completion date. Actual outcomes may substantially diverge from these assertions due to various known and unknown risks and uncertainties. Notably, the ongoing effects of the COVID-19 pandemic and challenges linked to general market conditions could impact DaVita's financial status and operation.

In summary, DaVita's decision to upsize its senior notes offering not only reflects its commitment to robust financial management but also highlights the company's proactive approach in navigating a complex healthcare landscape. As they journey towards the offering's closing, stakeholders await the potential impacts this financial maneuver could yield for both the company and its expansive patient base.